Literature DB >> 29482158

TIM-3 expression identifies a distinctive PD-1+ follicular helper T cell subset, with reduced interleukin 21 production and B cell help function in ovarian cancer patients.

Li Li1, Yan Ma2, Yuan Xu2, Kamalibaike Maerkeya2.   

Abstract

Follicular helper T (Tfh) cells are critical regulators of immune responses in several human malignancies. Their characteristics in ovarian cancer (OC) patients remain unclear. In this study, the circulating CD4+CXCR5+ Tfh cells was examined and compared in OC patients and non-cancer (NC) controls. Data showed that the frequency of PD-1+ Tfh cells was significantly higher in OC patients than in NC controls. Compared to PD-1- Tfh cells, PD-1+ Tfh cells presented higher interleukin (IL)-21 and IL-10 secretion and stronger proliferation. The PD-1+ Tfh cells from OC patients presented further increased IL-21 and IL-10 secretion than those from NC controls. When incubated with autologous naive B cells, PD-1+ Tfh cells from both OC patients and NC controls presented elevated capacity at inducing Ig secretion. Interestingly, TIM-3 expression was predominantly found in PD-1+ Tfh cells. Compared to TIM-3- PD-1+ Tfh cells, TIM-3+ PD-1+ Tfh cells presented significantly lower levels of IL-21 secretion and lower proliferation. In addition, TIM-3+ PD-1+ Tfh cells presented marked impairment in inducing IgM, IgG, and IgA secretion from B cells. Importantly, in OC patients, the frequencies of PD-1+ Tfh cells and TIM-3+ PD-1+ Tfh significantly enriched in tumor-infiltrating lymphocytes than in peripheral blood. Together, we demonstrated that Tfh cells could be subdivided into distinctive functional subsets based on PD-1 and TIM-3 expressions, and while PD-1 demarcated a potent Tfh subset, TIM-3 seemed to associate with reduced Tfh function.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Follicular helper T cell; IgG; Ovarian cancer; Tim-3

Mesh:

Substances:

Year:  2018        PMID: 29482158     DOI: 10.1016/j.intimp.2018.02.016

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

Review 1.  T cell help in the autoreactive germinal center.

Authors:  Elliot H Akama-Garren; Michael C Carroll
Journal:  Scand J Immunol       Date:  2022-05-31       Impact factor: 3.889

2.  Exploration of immune-related cells and ceRNA in squamous cell lung cancer.

Authors:  Lijun Wang; Hao Wang; Ke Xu; Yehong Xu; Yong Wang; Song Wei; Zhihong Zhang
Journal:  Medicine (Baltimore)       Date:  2021-09-03       Impact factor: 1.817

Review 3.  Insights into tertiary lymphoid structures in the solid tumor microenvironment: anti-tumor mechanism, functional regulation, and immunotherapeutic strategies.

Authors:  Hua Zhao; Hao Wang; Qiuru Zhou; Xiubao Ren
Journal:  Cancer Biol Med       Date:  2021-09-24       Impact factor: 5.347

4.  Serum checkpoint molecules in patients with IgG4-related disease (IgG4-RD).

Authors:  Haruki Matsumoto; Yuya Fujita; Naoki Matsuoka; Jumpei Temmoku; Makiko Yashiro-Furuya; Tomoyuki Asano; Shuzo Sato; Hiroshi Watanabe; Eiji Suzuki; Sosuke Tsuji; Shoichi Fukui; Masataka Umeda; Naoki Iwamoto; Atsushi Kawakami; Kiyoshi Migita
Journal:  Arthritis Res Ther       Date:  2021-05-24       Impact factor: 5.156

Review 5.  AllergoOncology: Role of immune cells and immune proteins.

Authors:  Mario Di Gioacchino; Loredana Della Valle; Alessandro Allegra; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Clin Transl Allergy       Date:  2022-03       Impact factor: 5.871

6.  Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma.

Authors:  Elaine Stur; Emine Bayraktar; Graziela Zibetti Dal Molin; Sherry Y Wu; Lingegowda S Mangala; Hui Yao; Ying Wang; Prahlad T Ram; Sara Corvigno; Hu Chen; Han Liang; Shelley S Tworoger; Douglas A Levine; Susan K Lutgendorf; Jinsong Liu; Kathleen N Moore; Keith A Baggerly; Beth Y Karlan; Anil K Sood
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.